2012
59IN Strategies to Optimize EGFR Therapies
Burtness B. 59IN Strategies to Optimize EGFR Therapies. Annals Of Oncology 2012, 23: ix42. DOI: 10.1016/s0923-7534(20)32673-9.Peer-Reviewed Original ResearchRecurrent/metastatic diseaseCombination of cetuximabCetuximab resistanceKinase inhibitorsMetastatic diseaseNeck cancerNuclear translocationInternational phase III trialReceptor tyrosine kinasesPhase III trialsSquamous cell carcinomaAugmentation of responsesDe novo resistanceH-ras mutationsMonoclonal antibody cetuximabTyrosine kinase inhibitorsK-ras mutationsFirst kinase inhibitorEpidermal growth factor receptorBristol-Myers SquibbGrowth factor receptorAdvanced headEGFR/HER2III trialsOral agents
1999
Analysis of K-ras, N-ras, H-ras, and p53 in Lung Neuroendocrine Neoplasms
Couce M, Bautista D, Costa J, Carter D. Analysis of K-ras, N-ras, H-ras, and p53 in Lung Neuroendocrine Neoplasms. Applied Immunohistochemistry & Molecular Morphology 1999, 8: 71-79. PMID: 10475381, DOI: 10.1097/00019606-199906000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAllelesDNA Mutational AnalysisExonsFemaleGenes, rasHumansImmunohistochemistryLung NeoplasmsMaleMiddle AgedMutation, MissenseNeuroendocrine TumorsPoint MutationPolymerase Chain ReactionPolymorphism, GeneticPolymorphism, Single-Stranded ConformationalRetrospective StudiesTumor Suppressor Protein p53ConceptsLarge cell neuroendocrine carcinomaPulmonary neuroendocrine tumorsAtypical carcinoidNeuroendocrine tumorsTypical carcinoidP53 geneK-rasCell neuroendocrine carcinomaSingle-strand conformation polymorphismHigh-grade tumorsHigh-grade carcinomaH-ras mutationsLung neuroendocrine neoplasmsN-rasK-ras mutationsH-RasExon 5Neuroendocrine carcinomaPolymerase chain reactionNeuroendocrine neoplasmsPositive immunostainingGenotypic mutationsN-ras geneTumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply